支架植入后抑制平滑肌细胞过度增殖的研究进展  

Research progress on inhibiting excessive proliferation of smooth muscle cells after stent implantation

作　　者：胡枝敏 凌望 吴美平[1] HU Zhimin;LING Wang;WU Meiping(Department of Cardiology,Shanghai University of Traditional Chinese Medicine Affiliated Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai200071,China)

机构地区：[1]上海中医药大学附属市中医医院心病科,上海200071

出　　处：《中国医药导报》2020年第7期27-30,共4页China Medical Herald

基　　金：国家自然科学基金面上项目(81673915、81973826);国家自然科学基金青年科学基金项目(81904167)。

摘　　要：支架内再狭窄(ISR)是限制支架植入术效果并严重影响患者生活质量的主要并发症,血管损伤部位的平滑肌细胞过度增殖是早期ISR形成的主要原因。药物涂层支架和生物可降解支架的问世虽然减轻了ISR危险程度,但是晚期并发症仍处于较高的水平,且生物可降解支架的适用材料还处于探索阶段。本文主要从抑制平滑肌细胞过度增殖的方面,总结平滑肌细胞在ISR进程中的相关机制及治疗手段,希望为临床治疗及实验研究提供思路。In-stent restenosis(ISR)is a major complication that limits the efficacy of stent implantation and seriously affects patients′quality of life.The excessive proliferation of smooth muscle cells at the site of vascular injury is the main reason for the formation of early ISR.Although the advent of drug-coated stents and biodegradable stents has reduced the risk of ISR,late complications are still at a high level,and the applicable materials of biodegradable stents are still in the exploration stage.This article mainly summarizes the related mechanisms and treatment methods of smooth muscle cells in the process of ISR from the aspect of inhibiting the excessive proliferation of smooth muscle cells,hoping to provide ideas for clinical treatment and experimental research.

关 键 词：支架内再狭窄 血管平滑肌细胞 研究进展 

分 类 号：R654.2[医药卫生—外科学]